What are the objectives to use AdnaTest?

AdnaTest Cancer offers a measurement for therapy success

With metastatic cancer patients must be treated quickly and effectively. The disappearance of circulating tumor cells is considered to be a measure of therapy success. In case there are remain CTCs in the blood during therapy, this indicates an early stage treatment failure. Thereby the physician may use the opportunity to respond faster than before and possibly adjust the treatment plan in order to prolong his patient’s life. Doctors may consider to use the AdnaTest diagnostic tool to monitor therapy in the adjuvant setting with advanced cancer, too.

The significance of AdnaTest is clinically proven in metastatic cancer

Efficient therapy monitoring has been demonstrated in a clinical trial (Tewes et al, 2008). 32 metastatic cancer patients were examined alongside the course of therapy using the AdnaTest cancer on CTC. In 16 patients the disappearance of CTC on therapy was observed (CTC- group), in the remaining 16 patients the presence of CTCs had no influence on the therapy (CTC+ group). Using a Kaplan Meyer analysis within the CTC+ group a statistically significant shorter overall survival was identified (Ø 230 days) – whereas the CTC- group survived on average longer than 600 days.


Kaplan-Meier overall survival (n = 32) in metastatic cancer patients, which during therapy while CTC persist show a significantly shortened overall survival (p = 0.0137

Further clinical evidence can be found at references